Latest Boehringer Ingelheim Corporation Stories

2014-03-01 12:20:30

For U.S. Media Only RIDGEFIELD, Conn., March 1, 2014 /PRNewswire/ -- Boehringer Ingelheim today presented data from Phase 3 studies of tiotropium delivered via the Respimat(®) inhaler in mild, moderate and severe asthma patients at the 2014 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting in San Diego. Tiotropium is being studied to determine its efficacy and safety in treating asthma patients and is not currently approved for this indication. The first results...

2014-01-30 12:28:26

Unique academic-industry partnership will include an IPF patient registry and biomarker bank RIDGEFIELD, Conn. and DURHAM, N.C., Jan. 30, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Duke Clinical Research Institute (DCRI) have formed a unique collaborative relationship to uncover insights into idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. As part of the partnership, Boehringer Ingelheim and Duke Clinical Research Institute will...

Word of the Day
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.